These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21824567)

  • 1. Hunter disease before and during enzyme replacement therapy.
    Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E
    Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidisciplinary management of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Escolar ML; Giugliani R; Guffon NH; Harmatz P; Kamin W; Kampmann C; Koseoglu ST; Link B; Martin RA; Molter DW; Muñoz Rojas MV; Ogilvie JW; Parini R; Ramaswami U; Scarpa M; Schwartz IV; Wood RE; Wraith E
    Pediatrics; 2009 Dec; 124(6):e1228-39. PubMed ID: 19901005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
    Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
    Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
    Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
    Marín LL; Gutiérrez-Solana LG; Fernández AT
    Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
    Burton BK; Whiteman DA;
    Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical practice guideline for the management of Hunter syndrome. Hunter España working group].
    Guillén-Navarro E; Blasco AJ; Gutierrez-Solana LG; Couce ML; Cancho-Candela R; Lázaro P;
    Med Clin (Barc); 2013 Nov; 141(10):453.e1-13. PubMed ID: 24060500
    [No Abstract]   [Full Text] [Related]  

  • 11. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of enzyme replacement therapy with idursulfase].
    Gutiérrez-Solana LG
    Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
    Papadia F; Lozupone MS; Gaeta A; Capodiferro D; Lacalendola G
    Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):253-8. PubMed ID: 21528770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
    Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
    Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy.
    Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR
    Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704
    [No Abstract]   [Full Text] [Related]  

  • 18. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy.
    Filippon L; Wayhs CA; Atik DM; Manfredini V; Herber S; Carvalho CG; Schwartz IV; Giugliani R; Vargas CR
    Mutat Res; 2011 Apr; 721(2):206-10. PubMed ID: 21334454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
    Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B
    Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucopolysaccharidosis type II (Hunter disease): identification and characterization of eight point mutations in the iduronate-2-sulfatase gene in Japanese patients.
    Sukegawa K; Tomatsu S; Fukao T; Iwata H; Song XQ; Yamada Y; Fukuda S; Isogai K; Orii T
    Hum Mutat; 1995; 6(2):136-43. PubMed ID: 7581397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.